Drug Profile
PDE 4 inhibitor - Eli Lilly and Company
Latest Information Update: 28 Apr 2021
Price :
$50
*
At a glance
- Originator Eli Lilly and Company
- Class Small molecules
- Mechanism of Action Type 4 cyclic nucleotide phosphodiesterase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Autoimmune disorders
Most Recent Events
- 28 Apr 2021 No recent reports of development identified for phase-I development in Autoimmune-disorders in USA
- 09 Mar 2018 Phase-I clinical trials in Autoimmune disorders in USA (unspecified route) (Eli Lilly pipeline, March 2018)